NCT06231732 The Hi-tACS on Cognitive Function in Patients With Schizophrenia: a Pilot Study
| NCT ID | NCT06231732 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sir Run Run Shaw Hospital |
| Condition | Schizophrenia |
| Study Type | INTERVENTIONAL |
| Enrollment | 12 participants |
| Start Date | 2023-11-14 |
| Primary Completion | 2024-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 12 participants in total. It began in 2023-11-14 with a primary completion date of 2024-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a double-blind, randomized, controlled intervention study aimed at exploring whether high-frequency transcranial alternating current stimulation (Hi-tACS) can improve cognitive impairment in patients with schizophrenia.
Eligibility Criteria
Inclusion Criteria: 1. Meets the diagnostic criteria for schizophrenia according to DSM-5. 2. Age ≥ 18 years old. 3. Right-handed. 4. Willing to participate in this study and sign an informed consent form. If the participant is unable to read and sign the informed consent form due to lack of capacity, a legal guardian must act as a proxy during the informed consent process and sign the form. 5. Clinically stable, receiving antipsychotic medication treatment with a stable dose for 4 weeks without any changes. 6. Montreal Cognitive Assessment score ≥ 10 points. Exclusion Criteria: 1. Psychotic disorders caused by split affective disorder, bipolar disorder, intellectual disability, anxiety spectrum disorders, drugs, alcohol, and other psychoactive substances according to DSM-V diagnostic criteria. 2. Those with severe or unstable organic diseases, with a history of brain tumors or epilepsy. 3. Those who have received MECT or TMS treatment within 1 month before enrollment. 4. Skin integrity at the electrode placement site is compromised. Allergy to electrode gel or adhesive. 5. Implants of metal or electronic devices (such as pacemakers, cochlear implants, deep brain stimulators, aneurysm clips, internal fixation devices after ventriculoperitoneal shunt surgery, etc.). 6. Participation in any other clinical trials within 1 month prior to baseline. 7. Pregnant and lactating women. 8. The investigator believes that there are inappropriate conditions for participating in this study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06231732 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Schizophrenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06231732 currently recruiting?
Yes, NCT06231732 is actively recruiting participants. Contact the research team at tangjinsong@zju.edu.cn for enrollment information.
Where is the NCT06231732 trial being conducted?
This trial is being conducted at Hanzhou, China.
Who is sponsoring the NCT06231732 clinical trial?
NCT06231732 is sponsored by Sir Run Run Shaw Hospital. The trial plans to enroll 12 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.